Dr. Ian Davis on 5-year enzalutamide survival data in mHSPC

Ian D. Davis, MBBS, PhD, FRACP, FAChPM, of the Eastern Health Clinical School at Monash University in Box Hill, Australia, discusses results of the abstract, “Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC),” which he shared during the 2022 ASCO Annual Meeting (abstract LBA5004).

Related Videos
Madison Novosel, BA, in an interview with Urology Times
Veda Giri, MD, answers a question during a Zoom video interview
Dr. Bertrand F. Tombal in an interview with Urology Times
Related Content
© 2023 MJH Life Sciences

All rights reserved.